NCT01787500View on ClinicalTrials.gov

Vemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

February 15, 2013

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions
BRAF NP_004324.2:p.V600XKRAS wt AlleleMetastatic Malignant Solid NeoplasmStage IV Colorectal Cancer AJCC v7Stage IVA Colorectal Cancer AJCC v7Stage IVB Colorectal Cancer AJCC v7Unresectable Solid Neoplasm
Interventions
BIOLOGICAL

Cetuximab

Given IV

DRUG

Irinotecan Hydrochloride

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacological Study

Correlative studies

DRUG

Vemurafenib

Given PO

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Genentech, Inc.

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER